

ICMJE DISCLOSURE FORM

Date: October 3, 2021

Your Name: Mikael Norman

Manuscript Title: The Swedish Neonatal Network for Outcomes Improvement

Manuscript number (if known): PM-2020-NNOI-01(PM-21-62) R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Region Stockholm and Karolinska Institutet (ALF 2020-0443)	Funding
		The Childhood Foundation of the Swedish Order of Freemasons	Funding
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	Chiesi Pharma AB, Sweden	Funding
3	Royalties or licenses	Studentlitteratur AB, Sweden	Royalties

		Liber AB, Sweden	Royalties
4	Consulting fees	Swedish Medical Journal	Consultancy
		Swedish Patient Insurance	Consultancy
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Chiesi Pharma AB	Lecture fee
6	Payment for expert testimony	___ None	
7	Support for attending meetings and/or travel	___ None	
8	Patents planned, issued or pending	___ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	___ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	___ None	
11	Stock or stock options	Eva & Mikael Norman AB	Family company
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	___ None	
13	Other financial or non-financial interests	___ None	

Please summarize the above conflict of interest in the following box:

Mikael Norman reports funding from Region Stockholm and Karolinska Institutet (ALF 2020-0443); The Childhood Foundation of the Swedish Order of Freemasons and Chiesi Pharma AB; royalties from Studentlitteratur AB and Liber AB in Sweden; consultancy for Swedish Medical Journal and Swedish Patient Insurance; receipt of a lecture fee from Chiesi Pharma AB, and stocks in Eva & Mikael Norman AB.

Please place an "X" next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: October 3, 2021

Your Name: Stellan Håkansson

Manuscript Title: The Swedish Neonatal Network for Outcomes Improvement

Manuscript number (if known): PM-2020-NNOI-01(PM-21-62) R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	SNQ/Karolinska University Hospital	Consultancy
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	Essum AB	Family company
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	

Please summarize the above conflict of interest in the following box:

Stellan Håkansson reports consultancy for the Swedish Neonatal Quality Register and shareholding in Essum AB.

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.